MedPath
HSA Approval

LINEZOLID KABI SOLUTION FOR INFUSION 2MG/ML

SIN15849P

LINEZOLID KABI SOLUTION FOR INFUSION 2MG/ML

LINEZOLID KABI SOLUTION FOR INFUSION 2MG/ML

November 2, 2019

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS KABI (SINGAPORE) PTE LTD
Licence HolderFRESENIUS KABI (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION

INTRAVENOUS

Medical Information

J01XX08

linezolid

Manufacturer Information

FRESENIUS KABI (SINGAPORE) PTE LTD

Fresenius Kabi Norge AS

Active Ingredients

Linezolid

2mg/ml

Linezolid

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LINEZOLID KABI SOLUTION FOR INFUSION 2MG/ML - HSA Approval | MedPath